|
|
 |
|
| Test Name: | MET exon 14 Skipping Mutation Detection |
| Compliance: | LDT |
| Test Description: | MET exon 14 skipping mutation is present in 3% to 4% of lung adenocarcinomas. In preclinical and clinical studies, responses to MET inhibitors have been reported in patients with lung cancer with MET exon 14 skipping mutation as a primary driver. Besides, MET exon 14 skipping mutation is also involved in acquired resistance to epidermal growth factor receptor inhibitors. |
| Methodology: | PCR-Sanger sequencing analysis of exon 14 of the MET gene |
| Gene Name: | MET |
| Protein Name: | |
| Specimen Requirements: | FFPE tissue slides (4µm) |
| Storage Condition: | Ambient Temperature |
| Turn Around Time: | 5 working days from day of specimen received |
| OMIM: | |
| Genetic Home Reference: | |
|
|
|
|
|
|
|
|
Shipping & Billing Information
|
Non-disclosure and Complaints
All data/information generated from within/related to HKMPDC and our customers are treated in strict confidence in accordance with the Personal Data (Privacy) Ordinance of Hong Kong. If you have a complaint, please contact us at the (852) 2986 1213 or email us at contact@hk-mpdc.com. All communications with HKMPDC would be dealt with in strict confidence.
Notice of Privacy Practices
This notice describes how medical information about you may be used and disclosed.
Personal health information or related information released to HKMPDC relating to the services requested may be subjected to re-disclosure by HKMPDC to health care providers, such as doctors, nurses, and others involved in the delivery of the services.
We may also disclose medical information about you to authorised public health or government officials for public health activities as required by law and accreditation body.
Copyright © 2013 香港分子病理檢驗中心 Hong Kong Molecular Pathology Diagnostic Centre Limited (HKMPDC). All Rights Reserved.
Information Updated 1 July, 2023.
|
|
|
|
